ARS Pharmaceuticals, Inc. SPRY Other Nonoperating Expense
Other Nonoperating Expense at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingExpense.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s other nonoperating expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s other nonoperating expense?
- ARS Pharmaceuticals, Inc. (SPRY) reported other nonoperating expense of $2.44M in Q1 2026.
- What does other nonoperating expense mean?
- This represents costs incurred that are not related to the primary operating activities of the business, such as interest expense on debt or losses on asset disposals. It is a key indicator of the company's financial leverage and the cost of maintaining its capital structure. High levels of these expenses can indicate significant debt burdens or non-recurring operational headwinds.